Abstract:Traditionally, the treatment of anemia associated with chronic kidney disease (CKD) involves prescribing erythropoiesis-stimulating agents (ESAs) or iron preparations. The effectiveness and safety of ESAs and iron have been established. However, several clinical issues, such as hyporesponsiveness to ESAs or defective iron utilization for erythropoiesis, have been demonstrated. Recently, a new class of therapeutics for renal anemia known as hypoxia-inducible factor (HIF)/proline hydroxylase (PH) inhibitors has been developed. Several studies have reported that HIF-PH inhibitors have unique characteristics compared with those of ESAs. In particular, the use of HIF-PH inhibitors may maintain target Hb concentration in patients treated with a high dose of ESAs without increasing the dose. Furthermore, several recent studies have demonstrated that patients with CKD with defective iron utilization for erythropoiesis had a high risk of cardiovascular events or premature death. HIF-PH inhibitors increase iron transport and absorption from the gastrointestinal tract; thus, they may ameliorate defective iron utilization for erythropoiesis in patients with CKD. Conversely, several clinical problems, such as aggravation of thrombotic and embolic complications, diabetic retinal disease, and cancer, have been noted at the time of HIF-PH inhibitor administration. Recently, several pooled analyses of phase III trials have reported the non-inferiority of HIF-PH inhibitors regarding these clinical concerns compared with ESAs. The advantages and issues of anemia treatment by ESAs, iron preparations, and HIF-PH inhibitors must be fully understood. Moreover, patients with anemia and CKD should be treated by providing a physiological erythropoiesis environment that is similar to that of healthy individuals.

New expectations in the treatment of anemia in chronic kidney disease

Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents

Current and future chemical therapies for treating anaemia in chronic kidney disease

Innovations thérapeutiques dans la prise en charge de l’anémie de la maladie rénale chronique Therapeutic innovations in the management of chronic kidney disease-associated anemia

Current Status of Renal Anemia Pharmacotherapy-What Can We Offer Today

Investigational therapies for renal disease-induced anemia

Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?

Emerging drugs for chronic kidney disease

Design and optimization strategies for the development of new drugs that treat chronic kidney disease

Treatment of Anemia Associated with Chronic Kidney Disease: Plea for Considering Physiological Erythropoiesis

Treatment Options for Anemia in Kidney Transplant Patients: A Review

Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

[Clinical application and future perspectives of HIF-PH inhibitors]

[New developments in anaemia treatment - erythropoietin versus prolyl hydroxylase inhibitors?]

Gut Dysbiosis and Its Role in the Anemia of Chronic Kidney Disease

Anaemia in CKD-treatment standard

Transgenic augmentation of erythroferrone in mice ameliorates anemia in adenine-induced chronic kidney disease

Present and Future in the Treatment of Diabetic Kidney Disease

The role of roxadustat in chronic kidney disease patients complicated with anemia

Stabilizing Hypoxia-Inducible Factor to Manage Anemia in Chronic Kidney Disease: From Basic Theory to Clinical Study

Iron Therapies For Iron Deficiency In Chronic Kidney Disease: A Literature Review